388 related articles for article (PubMed ID: 23991894)
1. Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases.
Wang Z; Patel DJ
Q Rev Biophys; 2013 Nov; 46(4):349-73. PubMed ID: 23991894
[TBL] [Abstract][Full Text] [Related]
2. Targeting histone lysine methylation in cancer.
McGrath J; Trojer P
Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
[TBL] [Abstract][Full Text] [Related]
3. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.
Tian X; Zhang S; Liu HM; Zhang YB; Blair CA; Mercola D; Sassone-Corsi P; Zi X
Curr Cancer Drug Targets; 2013 Jun; 13(5):558-79. PubMed ID: 23713993
[TBL] [Abstract][Full Text] [Related]
4. Oncoepigenomics: making histone lysine methylation count.
Decarlo D; Hadden MK
Eur J Med Chem; 2012 Oct; 56():179-94. PubMed ID: 22975593
[TBL] [Abstract][Full Text] [Related]
5. Development of homogeneous nonradioactive methyltransferase and demethylase assays targeting histone H3 lysine 4.
Gauthier N; Caron M; Pedro L; Arcand M; Blouin J; Labonté A; Normand C; Paquet V; Rodenbrock A; Roy M; Rouleau N; Beaudet L; Padrós J; Rodriguez-Suarez R
J Biomol Screen; 2012 Jan; 17(1):49-58. PubMed ID: 21940714
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for substrate recognition by lysine methyltransferases and demethylases.
Del Rizzo PA; Trievel RC
Biochim Biophys Acta; 2014 Dec; 1839(12):1404-15. PubMed ID: 24946978
[TBL] [Abstract][Full Text] [Related]
7. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
8. Histone lysine methylation dynamics: establishment, regulation, and biological impact.
Black JC; Van Rechem C; Whetstine JR
Mol Cell; 2012 Nov; 48(4):491-507. PubMed ID: 23200123
[TBL] [Abstract][Full Text] [Related]
9. Targeting Histone Methylation in Cancer.
McCabe MT; Mohammad HP; Barbash O; Kruger RG
Cancer J; 2017; 23(5):292-301. PubMed ID: 28926430
[TBL] [Abstract][Full Text] [Related]
10. Assessing histone demethylase inhibitors in cells: lessons learned.
Hatch SB; Yapp C; Montenegro RC; Savitsky P; Gamble V; Tumber A; Ruda GF; Bavetsias V; Fedorov O; Atrash B; Raynaud F; Lanigan R; Carmichael L; Tomlin K; Burke R; Westaway SM; Brown JA; Prinjha RK; Martinez ED; Oppermann U; Schofield CJ; Bountra C; Kawamura A; Blagg J; Brennan PE; Rossanese O; Müller S
Epigenetics Chromatin; 2017; 10():9. PubMed ID: 28265301
[TBL] [Abstract][Full Text] [Related]
11. Examining the impact of gene variants on histone lysine methylation.
Van Rechem C; Whetstine JR
Biochim Biophys Acta; 2014 Dec; 1839(12):1463-76. PubMed ID: 24859469
[TBL] [Abstract][Full Text] [Related]
12. Cell-based assays to support the profiling of small molecules with histone methyltransferase and demethylase modulatory activity.
Martinez NJ; Simeonov A
Drug Discov Today Technol; 2015 Nov; 18():9-17. PubMed ID: 26723887
[TBL] [Abstract][Full Text] [Related]
13. The future therapeutic potential of histone demethylases: A critical analysis.
Natoli G; Testa G; De Santa F
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620
[TBL] [Abstract][Full Text] [Related]
14. Insights into the epigenetic mechanisms involving histone lysine methylation and demethylation in ischemia induced damage and repair has therapeutic implication.
Chakravarty S; Jhelum P; Bhat UA; Rajan WD; Maitra S; Pathak SS; Patel AB; Kumar A
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):152-164. PubMed ID: 27664837
[TBL] [Abstract][Full Text] [Related]
15. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors.
Spannhoff A; Hauser AT; Heinke R; Sippl W; Jung M
ChemMedChem; 2009 Oct; 4(10):1568-82. PubMed ID: 19739196
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic small molecule modulators of histone and DNA methylation.
Hauser AT; Robaa D; Jung M
Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of histone lysine methylation: structures of methyl writers and erasers.
Upadhyay AK; Cheng X
Prog Drug Res; 2011; 67():107-24. PubMed ID: 21141727
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.
Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM
Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.
Tsai CT; So CW
Oncogene; 2017 Mar; 36(13):1753-1759. PubMed ID: 27593928
[TBL] [Abstract][Full Text] [Related]
20. Tipping the lysine methylation balance in disease.
Black JC; Whetstine JR
Biopolymers; 2013 Feb; 99(2):127-35. PubMed ID: 23175387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
